WASHINGTON and NASHUA, N.H., Oct. 21 /PRNewswire-FirstCall/ -- iCAD(R), Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions announced they are collaborating with George Washington University Medical Center (GW) on a digital mammography van, or ‘mammovan,’ to bring digital mammography technology to women in the Northern Virginia, D.C. and Maryland communities. This new van, equipped with iCAD’s Second Look(R) Digital System in conjunction with Hologic’s Selenia digital mammography sensor, replaces a ten year old van with no digital mammography capabilities. This participation signifies iCAD’s continued dedication to promoting nationwide adoption of digital mammography during the nation’s Breast Cancer Awareness Month.
“It is a very exciting program and time for us. Not only does this new mammovan replace the one we have had for the past 10 years, but I also believe we are the longest serving mobile mammography program in this region,” said Dr. Rachel Brem, Director of Breast Imaging and Intervention, Professor of Radiology and the Vice-Chairman in the Department of Radiology at GW. “We are very excited to continue this program and to have the newest and most effective technology from iCAD on the van.”
The van is offered to the public and serves many underserved communities, including African-American, Korean and Hispanic. It features a patient navigator to help patients through the screening process and to identify the appropriate mechanism for further treatment, be it diagnostic mammogram, biopsy, or others. The van also serves corporate sites to maximize access and serve women at various corporations.
“This is iCAD’s first time participating in a mammovan and we are honored to be a part of it,” said W. Scott Parr, president and CEO of iCAD, Inc. “This program is perfectly parallel to our organization’s commitment to help make digital mammography available to all patients, regardless of their location or medical affiliation. We hope that through this initiative, more women can be screened for breast cancer and more lives can be saved.”
Studies show that iCAD’s internally-developed CAD technology has the ability to help detect breast cancer nearly 15 months earlier than screening mammography alone. Described by leading health insurance providers in the United States as a ‘standard of care’ in large radiology practices and a ‘medically necessary adjunct to mammography,’ CAD continues to receive strong support from radiologists, the American College of Radiology and patient advocacy groups worldwide.
About George Washington University Medical Center
The George Washington University Medical Center is an internationally recognized interdisciplinary academic health center which has consistently provided high quality medical care in the Washington, D.C. metropolitan area. The Medical Center comprises the School of Medicine and Health Sciences, the 11th oldest medical school in the country; the School of Public Health and Health Services, the only such school in the nation’s capital; GW Hospital, jointly owned and operated by a partnership between The George Washington University and Universal Health Services, Inc.; and GW Medical Faculty Associates, an independent faculty practice plan. For more information on GWUMC, visit http://www.gwumc.edu.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan’s Growth Strategy Leadership award, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over eleven hundred women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “anticipate,” “likely,” and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD and SecondLook are registered trademarks and TotalLook is a trademark of iCAD, Inc.
For iCAD investor relations, contact Kevin McGrath of Cameron Associates at +1 212 245 4577 or via email at kevin@cameronassoc.com.
For all other inquiries, contact Monica Pandolfi of SHIFT Communications at +1 617 681 1235 or via email at mpandolfi@shiftcomm.com.
iCAD, Inc.
CONTACT: iCAD investor relations, Kevin McGrath of Cameron Associates,+1-212-245-4577, kevin@cameronassoc.com; or Monica Pandolfi of SHIFTCommunications, +1-617-681-1235, mpandolfi@shiftcomm.com
